-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7

Benzinga·04/28/2026 17:41:33
Listen to the news
Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.